Watson Pharmaceuticals, Inc. announced that the US pilot study evaluating Uracyst (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.

"Unfortunately, the results of the pilot study failed to demonstrate efficacy despite numerical separation of response between Uracyst and placebo on certain measurements," said Fred Wilkinson, Watson's executive vice president, global brands. "We will work with Stellar Pharmaceuticals Inc. to further evaluate the response and assist in determining any next steps, but at this time we do not plan to allocate any additional resources to further pursue this development programme. While regrettable, our decision will permit Watson to strategically refocus development resources on other product candidates in our development portfolio."

Interstitial cystitis is a chronic inflammatory disease of the bladder wall which causes pain, discomfort and frequent and urgent urination for those afflicted. The etiology of the disease is unknown. There is no known cure for the IC and currently approved products attempt to alleviate the symptoms of the disease. The quality of life for patients with IC is extremely poor, as they may need to void up to 60 times per day.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health.